Phase II trial of target-guided personalized chemotherapy in first-line metastatic colorectal

被引：0
|
作者：
Cubillo, Antonio
Rodriguez-Pascual, Jesus
Lopez-Rios, Fernando
Plaza, Carlos
Garcia, Elena
Alvarez-Gallego, Rafael
De Vicente, Emilio
Quijano, Yolanda
Hernando, Ovidio
Rubio, Carmen
Hidalgo, Manuel
机构：
[1] Ctr Integral Oncol Clara Campal, Madrid, Spain
[2] Therapeut Targets Lab, Madrid, Spain
[3] Spanish Natl Canc Res Ctr CNIO, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3543
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer
    Cubillo, Antonio
    Rodriguez-Pascual, Jesus
    Lopez-Rios, Fernando
    Plaza, Carlos
    Garcia, Elena
    Alvarez, Rafael
    de Vicente, Emilio
    Quijano, Yolanda
    Hernando, Ovidio
    Rubio, Carmen
    Perea, Sofia
    Sanchez, Gema
    Hidalgo, Manuel
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (03): : 236 - 242
  • [2] PHASE II TRIAL OF TARGET-GUIDED PERSONALIZED CHEMOTHERAPY IN FIRST LINE METASTATIC COLORECTAL
    Cubillo, Antonio
    Rodriguez-Pascual, Jesus
    Lopez-Rios, Fernando
    Plaza Lopez, Carlos
    Garcia, Elena
    Alvarez, Rafael
    Vicente, De Emilio
    Quijano, Yolanda
    Hernando, Ovidio
    Rubio, Carmen
    Hidalgo, Manuel
    ANNALS OF ONCOLOGY, 2012, 23 : 24 - 24
  • [3] Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients
    Bécouarn, Y
    Ychou, M
    Ducreux, M
    Borel, C
    Bertheault-Cvitkovic, F
    Seitz, JF
    Nasca, S
    Nguyen, TD
    Paillot, B
    Raoul, JL
    Duffour, J
    Fandi, A
    Dupont-André, G
    Rougier, P
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) : 2739 - 2744
  • [4] Raltitrexed plus oxaliplatin as first-line chemotherapy in metastatic colorectal carcinoma: a multicentric phase II trial
    Neri, B
    Doni, L
    Fulignati, C
    Perfetto, F
    Turrini, M
    Andreoli, F
    Pantalone, D
    Pernice, LM
    Taruffi, F
    Martini, V
    Poma, A
    Valeri, A
    Bacci, G
    Sancez, L
    Moretti, R
    ANTI-CANCER DRUGS, 2002, 13 (07) : 719 - 724
  • [5] A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer
    Xiong, Jian Ping
    Zhang, Ling
    Zhong, Lu Xing
    Qiu, Feng
    Xu, Jun
    Tao, Qing Song
    Xiang, Xiao Jun
    Yu, Feng
    Tang, Xiao Mei
    ANTI-CANCER DRUGS, 2007, 18 (09) : 1103 - 1107
  • [6] Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients
    Ghosn, M
    Kattan, J
    Farhat, F
    Younes, F
    Gasmi, J
    ANTICANCER RESEARCH, 2006, 26 (3B) : 2451 - 2456
  • [7] A phase II trial of gemcitabine combined with vinorelbine as first-line chemotherapy for metastatic breast cancer
    Meshref, M. M.
    Samir, S.
    Saad, E.
    Gouda, Y.
    Elmesidy, S.
    Koheil, H.
    Elzawahri, H.
    Kandil, A.
    Abdelhamid, T.
    Zaki, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Optimizing first-line chemotherapy for metastatic colorectal cancer
    Adams, Richard A.
    COLORECTAL CANCER, 2012, 1 (03) : 241 - 253
  • [9] Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy
    Rose, Tracy L.
    Chism, David D.
    Alva, Ajjai S.
    Deal, Allison M.
    Maygarden, Susan J.
    Whang, Young E.
    Kardos, Jordan
    Drier, Anthony
    Basch, Ethan
    Godley, Paul A.
    Dunn, Mary W.
    Kim, William Y.
    Milowsky, Matthew I.
    BRITISH JOURNAL OF CANCER, 2018, 119 (07) : 801 - 807
  • [10] Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy
    Tracy L. Rose
    David D. Chism
    Ajjai S. Alva
    Allison M. Deal
    Susan J. Maygarden
    Young E. Whang
    Jordan Kardos
    Anthony Drier
    Ethan Basch
    Paul A. Godley
    Mary W. Dunn
    William Y. Kim
    Matthew I. Milowsky
    British Journal of Cancer, 2018, 119 : 801 - 807
12345